Stocktoria
Alector, Inc. ALEC
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-02-07
Alector, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -741.3% | -144.2% | -156.3% | -103.2% | -18.0% |
| Net margin | -679.2% | -118.4% | -134.3% | -99.8% | -17.5% |
| FCF margin | -874.7% | -229.9% | -192.1% | -18.3% | 142.6% |
| Return on assets | -48.7% | -25.4% | -21.0% | -16.9% | -4.5% |
| Return on equity | -466.3% | -93.9% | -97.2% | -62.2% | -12.1% |
| Debt / equity | 0.33× | 0.08× | 0.00× | — | — |
| Current ratio | 3.83 | 3.40 | 3.18 | 7.74 | 5.37 |
| Revenue growth | -79.1% | 3.6% | -27.3% | -35.5% | 881.5% |
Source: SEC EDGAR filings · CIK 0001653087 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.